Key result
Inclisiran achieves LDL-C reductions in real-world practice consistent with clinical trials.
Why the study?
This study aimed to compare the consistency of LDL-C reduction and safety profile of inclisiran between RCTs and real-world evidence.
Does the LDL-C lowering efficacy and safety profile of inclisiran in real-world settings demonstrate consistency with outcomes observed in randomized controlled trials in patients with ASCVD or HeFH?
Systematic Review (n=2,638)
Does the LDL-C lowering efficacy and safety profile of inclisiran in real-world settings demonstrate consistency with outcomes observed in randomized controlled trials in patients with ASCVD or HeFH?
Inclisiran demonstrates highly consistent LDL-C lowering efficacy and comparable safety in real-world clinical practice when compared to strictly controlled Phase III clinical trials.
Answers are grounded in this paper and cite their sources.
Supports real-world inclisiran use in ASCVD or HeFH; reinforces RCT evidence of consistent LDL-C reduction and safety.
Background: This study aimed to compare the consistency in low-density lipoprotein cholesterol (LDL-C) reduction and the safety profile of the novel lipid-lowering agent inclisiran between randomized controlled trials (RCTs) and real-world evidence (RWE). Methods: A systematic search of the PubMed, Embase, and Web of Science databases (2022-2025) identified three RCTs (n = 1833) and five RWE studies (n = 805). LDL-C reduction in the RCTs at 540 days was compared with that observed at 90 days in the RWE studies. Subgroup analyses were performed for patients with and without diabetes. Safety profiles were comparable across study types, with differences in adverse event incidence of less than 5%. Injection-site reactions were the most frequently reported adverse events. Conclusion: Inclisiran demonstrated highly consistent LDL-C-lowering efficacy and a comparable safety profile across both RCTs and real-world settings. The PROSPERO Registration: CRD42024618982, URL: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024618982.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) conducted a systematic review in Atherosclerotic cardiovascular disease (ASCVD) and Heterozygous familial hypercholesterolemia (HeFH) (n=2,638). Inclisiran vs. Randomized Controlled Trial (RCT) outcomes was evaluated on Consistency in relative LDL-C reduction between real-world evidence (RWE) and randomized controlled trials (RCTs) (p=0.75). Inclisiran demonstrated highly consistent low-density lipoprotein cholesterol reduction between real-world settings and randomized controlled trials, with no significant difference in efficacy observed.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: